Novo Nordisk next-gen shot shows 22% weight loss in early …
In December, Novo said its CagriSema drug, which is far more advanced in development than amycretin, led to 22.7% weight loss after 68 weeks, below the 25% the company had expected.
Novo Nordisk's next-gen obesity treatment hits target in early …
6 days ago · Novo said that patients on a high dose of the injectable form of the drug, called amycretin, lost 22% of their weight after 36 weeks, when analyzing the effects if all people adhered to treatment.
Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss
6 days ago · Novo Nordisk unveiled topline Phase Ib/IIa data Friday for its next-generation obesity treatment amycretin, which elicited up to 22% weight-loss in adults with overweight or obesity.. These early findings will help Novo redeem its obesity franchise after last month’s underwhelming late-stage readout of CagriSema, a GLP-1 and amylin analog that industry observers had been viewing as the ...
Novo Nordisk Obesity Drug Achieves Up to 22% Weight Loss in …
Novo Nordisk's (NVO) said Friday that its investigative weight loss drug, amycretin, led to a body weight reduction of up to 22% in an early-stage trial. The maker of obesity drug Wegovy and ...
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial - Forbes
Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight …
Dec 20, 2024 · Novo Nordisk said Friday that in the study of just over 3,400 patients, its new injectable weight loss drug CagriSema met its primary goal, with an average weight loss of 22.7% of a patient's...
What the results of Wegovy’s longest clinical trial yet show about ...
May 13, 2024 · New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how safe...
Daily pill cuts body weight by up to 13% after 3 months in
Sep 10, 2024 · A daily weight loss pill from Novo Nordisk was shown to lower body weight by up to 13% after three months in a Phase 1 clinical trial, according to findings presented Tuesday at the European...
Novo Nordisk's Wegovy weight loss drug wins UK approval for …
Jul 23, 2024 · The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy drug to reduce the risk of obese adults suffering from serious heart problems or strokes.